“Prep, or pre-exposure prophylaxis, is indicated for healthy subjects at high risk of being exposed to HIV. The assumption of this treatment, which is prescribed by the infectious disease specialist after a phase of counseling and discussion with the subject, can be carried out in two ways: the continuous one and the on-demand one”, as needed. “Depending on the frequency of exposure to risk, and needs, to be assessed on a case-by-case basis, the specialist will opt for one or the other method. If the subject who has undergone the Prep comes into contact with the virus, he will be protected from infection ”. This was stated by Laura Borgna, Hospital Care Business Unit and Policy & Market Access Director of Viatris Italia, on the sidelines of the press conference dedicated to issues related to the prevention of HIV infection, organized by Viatris Italia a few weeks after the announcement of the reimbursement of the Prep , prophylaxis treatment based on emtricitabine and tenofovir disoproxil, produced by Mylan, a group company.
“The reimbursement of the Prep – concludes Borgna – is an important step in the fight against the spread of the virus because it also allows the most vulnerable portion of the population at risk – who had limited access to this prevention option due to its cost, including young people for example – to be able to resort to it without any economic barriers”.
#Aids #Borgna #Viatris #Prep #prescribed #basis #HIV #risk #exposure #frequency